Trials / Completed
CompletedNCT00104078
Study Evaluating MYO-029 in Adult Muscular Dystrophy
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 108 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this phase I/II, multicenter, safety trial is to study MYO-029 in adult patients with muscular dystrophy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MYO-029 |
Timeline
- Start date
- 2005-02-01
- Completion
- 2007-01-01
- First posted
- 2005-02-23
- Last updated
- 2007-12-28
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00104078. Inclusion in this directory is not an endorsement.